The Impact of The Rads Assessment- Can Fewer Injections With Intravitreal Aflibercept Translate To Lower Overall Treatment Burden and Costs In Wamd When Compared With Intravitreal Ranibizumab?
Abstract
Authors
M Eriksson L Hagelund J Olsen H Heemstra J Carrasco